产品展示更多>>
- Deferasirox 201530-41-8
- Deferasirox 201530-41-8
Deferasirox 201530-41-8
产品描述 描述 Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. It is the first oral medication approved in the USA for this purpose.
纯度 99%储存/保存方法 Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.基本信息 别名 地拉罗司；ICL 670外观 白色至淡黄色性粉末可溶性/溶解性 DMSO : 69 mg/mL (184.8 mM)
Ethanol : 2 mg/mL (5.35 mM)生物活性 靶点 ironIn vitro(体外研究) In LX-2 cells treated with 50 μM deferasirox for 12 h, α1(I)procollagen expression is decreased by 25%, with maximal reductions (10-fold) seen following 24-120 h of treatment. Similarly, α-smooth muscle actin (αSMA) expression is significantly lower. Deferasirox had anti-proliferative effects on HL-60 or KG-1 myeloid leukemia cell lines at a concentration as low as 5 μM . The cytotoxicity is both dose and time dependent. The viability of both EL4 cells and L1210 cells incubated with deferasirox decrease in a concentration-dependent manner.In vivo(体内研究) The tumor is significantly smaller in the SIO mice treated with deferasirox compared with control. Mice treated with DFX showed longer survival than the other groups. Deferasirox has a survival benefit for SIO leukemia murine model in terms of iron chelation and antileukemic therapy.参考文献 参考文献 1. Wang T, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Oct;18(5):1359-64.
2. Ibrahim AS, et al. Curr Opin Infect Dis. 2008 Dec;21(6):620-5.
3. Devanur LD, et al. Biochem J. 2008 Jan 15;409(2):439-47.
研究领域 研究领域 CancerCancer MetabolismCancerTumor immunologyDrug DiscoverySmall Molecule DrugLead Compound DiscoveryDeferasirox 201530-41-8温馨提示：本产品仅作科研实验使用，不支持临床等研究